Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand

Table 1 Patient characteristics of the development, validation and non-tested EGFR-TKI-treated groups

	Development group		Validation group		Total		Non-tested EGFR-TKI treated group
	N	%	N	%	N	%	N	%
Total	1176	100	489	100	1665	100	129	100
Mutation status
No	927	78.8	399	81.6	1326	79.6	–	–
Yes	249	21.2	90	18.4	339	20.4	–	–
Mutation types
Exon 19 deletion Exon 21 L858R Exon 18 G719X Exon 18 G719X + Exon 20 S768I Exon 20 S768I Exon 20 S768I + Exon 21 L858R Exon 18 G719X + Exon 18 E709A Exon 21 L861Q Exon 20 R776C + Exon 21 L858R Exon 18 G719X + Exon 21 L861Q Exon 19 deletion + Exon 20 S768I	117 102 12 7 2 3 2 1 1 1 1	47.0 41.0 4.8 2.8 0.8 1.2 0.8 0.4 0.4 0.4 0.4	47 35 3 3 1 0 0 1 0 0 0	52.2 38.9 3.3 3.3 1.1 0 0 1.1 0 0 0	164 137 15 10 3 3 2 2 1 1 1	48.4 40.4 4.4 3.0 0.9 0.9 0.6 0.6 0.3 0.3 0.3	–	–
Age at diagnosis
< 50 yr	74	6.3	40	8.2	114	6.9	15	11.6
50–59 yr	186	15.8	92	18.8	278	16.7	36	27.9
60–69 yr	361	30.7	167	34.2	528	31.7	46	35.7
70–79 yr	412	35.0	144	29.5	556	33.4	29	22.5
> =80 yr	143	12.2	46	9.4	189	11.4	3	2.3
Sex
Male	513	43.6	218	44.6	731	43.9	54	41.9
Female	663	56.4	271	55.4	934	56.1	75	58.1
Ethnicity
NZ European	682	58.0	293	59.9	975	58.6	75	58.1
NZ Maori	175	14.9	68	13.9	243	14.6	20	15.5
Pacific	127	10.8	53	10.8	180	10.8	13	10.1
Asian	177	15.1	68	13.9	245	14.7	20	15.5
Other & Unknown	15	1.3	7	1.4	22	1.3	1	0.8
Smoking
Current smoker	264	22.5	112	22.9	376	22.6	29	22.5
Non-smoker	308	26.2	116	23.7	424	25.5	41	31.8
Ex-smoker	604	51.4	261	53.4	865	52.0	59	45.7
Extent
Localised	130	11.1	37	7.6	167	10.0	2	1.6
Adjacent or regional	266	22.6	120	24.5	386	23.2	22	17.1
Distant	561	47.7	232	47.4	793	47.6	80	62.0
Unknown	219	18.6	100	20.5	319	19.2	25	19.4
Histology
Adenocarinoma	1024	87.1	433	88.6	1457	87.5	105	81.4
Other	152	12.9	56	11.5	208	12.5	24	18.6

ISSN: 1471-2407